Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT04864171
Recruiting Observational

REASSURE-NIRS Registry

NCT04864171 · tracked via the Priya Life Science Japan tracker
Sponsor
National Cerebral and Cardiovascular Center, Japan
Phase
Observational
Started
2018-10-09
Last updated
2025-08-15

Condition(s) studied

Lipid-Rich Atherosclerosis of Coronary Artery

Investigational drug(s) / intervention(s)

near-infrared spectroscopy

near-infrared spectroscopy: Near-infrared spectroscopy is an intravascular imaging device to visualize lipid-rich plaque of coronary artery.

Study summary

RESSURE-NIRS registry is designed to investigate clinical and pathophysiological characteristics of NIRS-derived lipid-rich plaque in patients with coronary artery disease. This is an on-going multi-center prospective registry in Japan.

Eligibility

Sex
ALL
Min age
20 Years
Max age
95 Years
Healthy volunteers
No
Inclusion Criteria: patients with coronary artery disease clinical indication for coronary angiography and/or percutaneous coronary intervention visualization of coronary lesions with NIRS Exclusion Criteria: poor quality of NIRS images

Primary outcome measure(s)

  • MACE — at an average of 3 year
    major adverse cardiovascular events (=cardiac-cause death, non-fatal MI and clinically-driven non-restenotic coronary revascularization)

Trial sites (2)

FacilityCityRegionStatus
Miyazaki Medical Association Hospital Miyazaki Japan Recruiting
National Cerebral & Cardiovascular Center Suita Japan Recruiting

More National Cerebral and Cardiovascular Center, Japan trials in Japan

Japanese Catheter Ablation Registry Recruiting
Japanese Lead Extraction Registry Recruiting
National Cerebral and Cardiovascular Center (NCVC) Stroke Registry Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04864171 on ClinicalTrials.gov ↗ ← All trials in Japan